首頁 > 市場調查報告書 > 製藥 > 感染疾病 > 金磚5國各國的感染免疫學市場展望(～2017年)

聯絡我們?

市場調查報告書

金磚5國各國的感染免疫學市場展望(～2017年)

Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017

出版商	GlobalData
出版日期	2012年01月	商品編碼	228219
內容資訊	英文 Pages: 135
價格	US $ 2500 PDF by E-mail (Single user license) US $ 5000 PDF by E-mail (Site license) US $ 7500 PDF by E-mail (Global license)

簡介
目錄
相關商品

金磚5國各國的感染免疫學市場展望(～2017年) 是由出版商GlobalData在2012年01月所出版的。這份英文市場調查報告書包含Pages: 135 價格從美金2500起跳。

簡介

本報告提供巴西、俄羅斯、印度、中國、南非的感染免疫學產品市場相關調查分析，各國、各感染疾病種類的收益實際成果與預測(～2017年)，流通管道及企業的市場佔有率，並彙整主要企業簡介等，為您概述為以下內容。

第1章目錄

第2章簡介

第3章金磚5國各國的感染免疫學市場

總收益(2003-2017年)
企業佔有率(2009-2010年)

第4章巴西的感染免疫學市場

總收益(2003-2017年)
肝炎病毒
其他病毒
反轉錄病毒
細菌
流通管道市場佔有率(2009-2010年)
企業佔有率(2009-2010年)

第5章俄羅斯的感染免疫學市場

總收益(2003-2017年)
肝炎病毒
反轉錄病毒
細菌
其他病毒
流通管道市場佔有率(2009-2010年)
企業佔有率(2009-2010年)

第6章印度的感染免疫學市場

總收益(2003-2017年)
肝炎病毒
反轉錄病毒
細菌
其他病毒
流通管道市場佔有率(2009-2010年)
企業佔有率(2009-2010年)

第7章中國的感染免疫學市場

總收益(2003-2017年)
反轉錄病毒
肝炎病毒
其他病毒
細菌
流通管道市場佔有率(2009-2010年)
企業佔有率(2009-2010年)

第8章南非的感染免疫學市場

總收益(2003-2017年)
反轉錄病毒
肝炎病毒
其他病毒
細菌
流通管道市場佔有率(2009-2010年)
企業佔有率(2009-2010年)

第9章主要企業概要:金磚5國各國的感染免疫學市場

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
bioMerieux S.A.
DiaSorin S.p.A
Qiagen N.V.
Shanghai Kehua Bio-engineering Co., Ltd.
Gen-Probe Incorporated
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Transasia Bio-Medicals Ltd.
Span Diagnostics Ltd.
Trivitron Healthcare Pvt Ltd.
Cellestis Limited
Alere Inc.
Hologic, Inc.

第10章附錄

圖表清單

GlobalData's new report, "Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017" provides key market data on the Infectious Immunology market in the BRICS countries. The report provides value ($m) data for each segment and sub-segment within four market categories - Hepatitis Viruses, Retroviruses, Other Virology and Bacteriology. The report also provides company shares and distribution shares data for the overall Infectious Immunology market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world's most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older-a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It's estimated that shortly after 2020, India's population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.

Scope

Market size data for Infectious Immunology market categories - Hepatitis Viruses, Retroviruses, Other Virology and Bacteriology.
Annualized market revenues ($m) data for each of the segments and sub-segments within the four market categories. Data from 2003 to 2010, forecast forward for seven years to 2017.
2010 company shares and distribution shares data for the overall Infectious Immunology market in each of the aforementioned countries.
Global corporate-level profiles of key companies operating within the Infectious Immunology market in BRICS.
Key players covered include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthcare, bioMerieux S.A.,DiaSorin S.p.A, Qiagen N.V., Shanghai Kehua Bio-engineering Co., Ltd., Gen-Probe Incorporated, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc. and Becton, Dickinson and Company.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the Infectious Immunology competitive landscape in BRICS.
Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7
1.2 List of Figures 10

2 Introduction 12

2.1 What is This Report About? 12

3 Infectious Immunology in BRICS 13

3.1 Infectious Immunology, BRICS, Overall Revenue ($m), 2003-2017 13
3.2 Infectious Immunology, BRICS, Company share (2009-2010) 19

4 Infectious Immunology In Brazil 21

4.1 Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 21
4.2 Hepatitis Viruses In Brazil 27

4.2.1 Hepatitis Viruses, Brazil, Overall Revenue (2003-2017) 27

4.3 Other Virology In Brazil 29

4.3.1 Other Virology, Brazil, Overall Revenue (2003-2017) 29

4.4 Retroviruses In Brazil 31

4.4.1 Retroviruses, Brazil, Overall Revenue (2003-2017) 31

4.5 Bacteriology In Brazil 33

4.5.1 Bacteriology, Brazil, Overall Revenue (2003-2017) 33

4.6 Infectious Immunology, Brazil, Distribution Share (2009-2010) 35
4.7 Infectious Immunology, Brazil, Company Share (2009-2010) 36

5 Infectious Immunology In Russian Federation 38

5.1 Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 38
5.2 Hepatitis Viruses In Russian Federation 44

5.2.1 Hepatitis Viruses, Russian Federation, Overall Revenue (2003-2017) 44

5.3 Retroviruses In Russian Federation 46

5.3.1 Retroviruses, Russian Federation, Overall Revenue (2003-2017) 46

5.4 Bacteriology In Russian Federation 48

5.4.1 Bacteriology, Russian Federation, Overall Revenue (2003-2017) 48

5.5 Other Virology In Russian Federation 50

5.5.1 Other Virology, Russian Federation, Overall Revenue (2003-2017) 50

5.6 Infectious Immunology, Russian Federation, Distribution Share (2009-2010) 52
5.7 Infectious Immunology, Russian Federation, Company Share (2009-2010) 53

6 Infectious Immunology In India 55

6.1 Infectious Immunology, India, Overall Revenue ($m), USD Actual, 2003-2017 55
6.2 Hepatitis Viruses In India 61

6.2.1 Hepatitis Viruses, India, Overall Revenue (2003-2017) 61

6.3 Retroviruses In India 63

6.3.1 Retroviruses, India, Overall Revenue (2003-2017) 63

6.4 Bacteriology In India 65

6.4.1 Bacteriology, India, Overall Revenue (2003-2017) 65

6.5 Other Virology in India 67

6.5.1 Other Virology, India, Overall Revenue (2003-2017) 67

6.6 Infectious Immunology, India, Distribution Share (2009-2010) 69
6.7 Infectious Immunology, India, Company Share (2009-2010) 70

7 Infectious Immunology In China 72

7.1 Infectious Immunology, China, Overall Revenue ($m), USD Actual, 2003-2017 72
7.2 Retroviruses In China 78

7.2.1 Retroviruses, China, Overall Revenue (2003-2017) 78

7.3 Hepatitis Viruses In China 80

7.3.1 Hepatitis Viruses, China, Overall Revenue (2003-2017) 80

7.4 Other Virology in China 82

7.4.1 Other Virology, China, Overall Revenue (2003-2017) 82

7.5 Bacteriology In China 84

7.5.1 Bacteriology, China, Overall Revenue (2003-2017) 84

7.6 Infectious Immunology, China, Distribution Share (2009-2010) 86
7.7 Infectious Immunology, China, Company Share (2009-2010) 87

8 Infectious Immunology In South Africa 89

8.1 Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 89
8.2 Retroviruses In South Africa 95

8.2.1 Retroviruses, South Africa, Overall Revenue (2003-2017) 95

8.3 Hepatitis Viruses In South Africa 97

8.3.1 Hepatitis Viruses, South Africa, Overall Revenue (2003-2017) 97

8.4 Other Virology in South Africa 99

8.4.1 Other Virology, South Africa, Overall Revenue (2003-2017) 99

8.5 Bacteriology In South Africa 101

8.5.1 Bacteriology, South Africa, Overall Revenue (2003-2017) 101

8.6 Infectious Immunology, South Africa, Distribution Share (2009-2010) 103
8.7 Infectious Immunology, South Africa, Company Share (2009-2010) 104

9 Overview of Key Companies in BRICS Infectious Immunology Market 106

9.1 Abbott Laboratories 106

9.1.1 Company Overview 106
9.1.2 Share in the BRICS Infectious Immunology Market 107

9.2 F. Hoffmann-La Roche Ltd. 108

9.2.1 Company Overview 108
9.2.2 Share in the BRICS Infectious Immunology Market 109

9.3 Siemens Healthcare 110

9.3.1 Company Overview 110
9.3.2 Share in the BRICS Infectious Immunology Market 111

9.4 bioMerieux S.A. 112

9.4.1 Company Overview 112
9.4.2 Share in the BRICS Infectious Immunology Market 113

9.5 DiaSorin S.p.A 114

9.5.1 Company Overview 114
9.5.2 Share in the BRICS Infectious Immunology Market 115

9.6 Qiagen N.V. 116

9.6.1 Company Overview 116
9.6.2 Share in the BRICS Infectious Immunology Market 117

9.7 Shanghai Kehua Bio-engineering Co., Ltd. 118

9.7.1 Company Overview 118
9.7.2 Share in the BRICS Infectious Immunology Market 118

9.8 Gen-Probe Incorporated 119

9.8.1 Company Overview 119
9.8.2 Share in the BRICS Infectious Immunology Market 120

9.9 Beckman Coulter, Inc. 121

9.9.1 Company Overview 121
9.9.2 Share in the BRICS Infectious Immunology Market 122

9.10 Bio-Rad Laboratories, Inc. 123

9.10.1 Company Overview 123
9.10.2 Share in the BRICS Infectious Immunology Market 124

9.11 Becton, Dickinson and Company 125

9.11.1 Company Overview 125
9.11.2 Share in the BRICS Infectious Immunology Market 126

9.12 PerkinElmer, Inc. 127

9.12.1 Company Overview 127

9.13 Thermo Fisher Scientific Inc. 127

9.13.1 Company Overview 127

9.14 Transasia Bio-Medicals Ltd. 127

9.14.1 Company Overview 127

9.15 Span Diagnostics Ltd. 128

9.15.1 Company Overview 128

9.16 Trivitron Healthcare Pvt Ltd. 128

9.16.1 Company Overview 128

9.17 Cellestis Limited 128

9.17.1 Company Overview 128

9.18 Alere Inc. 129

9.18.1 Company Overview 129

9.19 Hologic, Inc. 129

9.19.1 Company Overview 129

10 Appendix 130

10.1 Definitions of Markets Covered in the Report 131

10.1.1 Infectious Immunology 131

10.2 Research Methodology 132
10.3 Secondary Research 132
10.4 Primary Research 133
10.5 Models 133
10.6 Forecasts 134
10.7 Expert Panels 134
10.8 GlobalData Consulting 134
10.9 Currency Conversion 135
10.10 Contact Us 135
10.11 Disclaimer 135

List of Tables

1.1 List of Tables

Table 1: Infectious Immunology, BRICS, Overall Revenue ($m), 2003-2017 14
Table 2: Infectious Immunology, BRICS, Overall Revenue ($m), Historic, 2003-2010 16
Table 3: Infectious Immunology, BRICS, Overall Revenue ($m), Forecast, 2010-2017 18
Table 4: Infectious Immunology, BRICS, Company share by Revenue ($m), USD Actual, 2009-2010 20
Table 5: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 22
Table 6: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, Historic, 2003-2010 24
Table 7: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 26
Table 8: Hepatitis Viruses, Brazil, Revenue ($m), Historic, 2003-2010 27
Table 9: Hepatitis Viruses, Brazil, Revenue ($m), Forecast, 2010-2017 28
Table 10: Other Virology, Brazil, Revenue ($m), Historic, 2003-2010 29
Table 11: Other Virology, Brazil, Revenue ($m), Forecast, 2010-2017 30
Table 12: Retroviruses, Brazil, Revenue ($m), Historic, 2003-2010 31
Table 13: Retroviruses, Brazil, Revenue ($m), Forecast, 2010-2017 32
Table 14: Bacteriology, Brazil, Revenue ($m), Historic, 2003-2010 33
Table 15: Bacteriology, Brazil, Revenue ($m), Forecast, 2010-2017 34
Table 16: Infectious Immunology, Brazil, Distribution Share by Revenue ($m), USD Actual, 2009-2010 35
Table 17: Infectious Immunology, Brazil, Company share by Revenue ($m), USD Actual, 2009-2010 37
Table 18: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 39
Table 19: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, Historic, 2003-2010 41
Table 20: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 43
Table 21: Hepatitis Viruses, Russian Federation, Revenue ($m), Historic, 2003-2010 44
Table 22: Hepatitis Viruses, Russian Federation, Revenue ($m), Forecast, 2010-2017 45
Table 23: Retroviruses, Russian Federation, Revenue ($m), Historic, 2003-2010 46
Table 24: Retroviruses, Russian Federation, Revenue ($m), Forecast, 2010-2017 47
Table 25: Bacteriology, Russian Federation, Revenue ($m), Historic, 2003-2010 48
Table 26: Bacteriology, Russian Federation, Revenue ($m), Forecast, 2010-2017 49
Table 27: Other Virology, Russian Federation, Revenue ($m), Historic, 2003-2010 50
Table 28: Other Virology, Russian Federation, Revenue ($m), Forecast, 2010-2017 51
Table 29: Infectious Immunology, Russian Federation, Distribution Share by Revenue ($m), USD Actual, 2009-2010 52
Table 30: Infectious Immunology, Russian Federation, Company share by Revenue ($m), USD Actual, 2009-2010 54
Table 31: Infectious Immunology, India, Overall Revenue ($m), USD Actual, 2003-2017 56
Table 32: Infectious Immunology, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 58
Table 33: Infectious Immunology, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 60
Table 34: Hepatitis Viruses, India, Revenue ($m), Historic, 2003-2010 61
Table 35: Hepatitis Viruses, India, Revenue ($m), Forecast, 2010-2017 62
Table 36: Retroviruses, India, Revenue ($m), Historic, 2003-2010 63
Table 37: Retroviruses, India, Revenue ($m), Forecast, 2010-2017 64
Table 38: Bacteriology, India, Revenue ($m), Historic, 2003-2010 65
Table 39: Bacteriology, India, Revenue ($m), Forecast, 2010-2017 66
Table 40: Other Virology, India, Revenue ($m), Historic, 2003-2010 67
Table 41: Other Virology, India, Revenue ($m), Forecast, 2010-2017 68
Table 42: Infectious Immunology, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 43: Infectious Immunology, India, Company share by Revenue ($m), USD Actual, 2009-2010 71
Table 44: Infectious Immunology, China, Overall Revenue ($m), USD Actual, 2003-2017 73
Table 45: Infectious Immunology, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 75
Table 46: Infectious Immunology, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 77
Table 47: Retroviruses, China, Revenue ($m), Historic, 2003-2010 78
Table 48: Retroviruses, China, Revenue ($m), Forecast, 2010-2017 79
Table 49: Hepatitis Viruses, China, Revenue ($m), Historic, 2003-2010 80
Table 50: Hepatitis Viruses, China, Revenue ($m), Forecast, 2010-2017 81
Table 51: Other Virology, China, Revenue ($m), Historic, 2003-2010 82
Table 52: Other Virology, China, Revenue ($m), Forecast, 2010-2017 83
Table 53: Bacteriology, China, Revenue ($m), Historic, 2003-2010 84
Table 54: Bacteriology, China, Revenue ($m), Forecast, 2010-2017 85
Table 55: Infectious Immunology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 86
Table 56: Infectious Immunology, China, Company share by Revenue ($m), USD Actual, 2009-2010 88
Table 57: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 90
Table 58: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 92
Table 59: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 94
Table 60: Retroviruses, South Africa, Revenue ($m), Historic, 2003-2010 95
Table 61: Retroviruses, South Africa, Revenue ($m), Forecast, 2010-2017 96
Table 62: Hepatitis Viruses, South Africa, Revenue ($m), Historic, 2003-2010 97
Table 63: Hepatitis Viruses, South Africa, Revenue ($m), Forecast, 2010-2017 98
Table 64: Other Virology, South Africa, Revenue ($m), Historic, 2003-2010 99
Table 65: Other Virology, South Africa, Revenue ($m), Forecast, 2010-2017 100
Table 66: Bacteriology, South Africa, Revenue ($m), Historic, 2003-2010 101
Table 67: Bacteriology, South Africa, Revenue ($m), Forecast, 2010-2017 102
Table 68: Infectious Immunology, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 103
Table 69: Infectious Immunology, South Africa, Company share by Revenue ($m), USD Actual, 2009-2010 105
Table 70: Abbott Laboratories, Revenue ($m), BRICS Infectious Immunology Market, 2010 107
Table 71: F. Hoffmann-La Roche Ltd., Revenue ($m), BRICS Infectious Immunology Market, 2010 109
Table 72: Siemens Healthcare, Revenue ($m), BRICS Infectious Immunology Market, 2010 111
Table 73: bioMerieux S.A., Revenue ($m), BRICS Infectious Immunology Market, 2010 113
Table 74: DiaSorin S.p.A, Revenue ($m), BRICS Infectious Immunology Market, 2010 115
Table 75: Qiagen N.V., Revenue ($m), BRICS Infectious Immunology Market, 2010 117
Table 76: Shanghai Kehua Bio-engineering Co., Ltd., Revenue ($m), BRICS Infectious Immunology Market, 2010 118
Table 77: Gen-Probe Incorporated, Revenue ($m), BRICS Infectious Immunology Market, 2010 120
Table 78: Beckman Coulter, Inc., Revenue ($m), BRICS Infectious Immunology Market, 2010 122
Table 79: Bio-Rad Laboratories, Inc., Revenue ($m), BRICS Infectious Immunology Market, 2010 124
Table 80: Becton, Dickinson and Company, Revenue ($m), BRICS Infectious Immunology Market, 2010 126
Table 81: USD to Local Currency, BRICS, Average Exchange Rate, 2003-2010 135

List of Figures

1.2 List of Figures

Figure 1: Infectious Immunology, BRICS, Overall Revenue ($m), 2003-2017 13
Figure 2: Infectious Immunology, BRICS, Overall Revenue ($m), Historic, 2003-2010 15
Figure 3: Infectious Immunology, BRICS, Overall Revenue ($m), Forecast, 2010-2017 17
Figure 4: Infectious Immunology, BRICS, Company share (%), 2010 19
Figure 5: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 21
Figure 6: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, Historic, 2003-2010 23
Figure 7: Infectious Immunology, Brazil, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 25
Figure 8: Hepatitis Viruses, Brazil, Revenue ($m), Historic, 2003-2010 27
Figure 9: Hepatitis Viruses, Brazil, Revenue ($m), Forecast, 2010-2017 28
Figure 10: Other Virology, Brazil, Revenue ($m), Historic, 2003-2010 29
Figure 11: Other Virology, Brazil, Revenue ($m), Forecast, 2010-2017 30
Figure 12: Retroviruses, Brazil, Revenue ($m), Historic, 2003-2010 31
Figure 13: Retroviruses, Brazil, Revenue ($m), Forecast, 2010-2017 32
Figure 14: Bacteriology, Brazil, Revenue ($m), Historic, 2003-2010 33
Figure 15: Bacteriology, Brazil, Revenue ($m), Forecast, 2010-2017 34
Figure 16: Infectious Immunology, Brazil, Company share (%), 2010 36
Figure 17: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 38
Figure 18: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, Historic, 2003-2010 40
Figure 19: Infectious Immunology, Russian Federation, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 42
Figure 20: Hepatitis Viruses, Russian Federation, Revenue ($m), Historic, 2003-2010 44
Figure 21: Hepatitis Viruses, Russian Federation, Revenue ($m), Forecast, 2010-2017 45
Figure 22: Retroviruses, Russian Federation, Revenue ($m), Historic, 2003-2010 46
Figure 23: Retroviruses, Russian Federation, Revenue ($m), Forecast, 2010-2017 47
Figure 24: Bacteriology, Russian Federation, Revenue ($m), Historic, 2003-2010 48
Figure 25: Bacteriology, Russian Federation, Revenue ($m), Forecast, 2010-2017 49
Figure 26: Other Virology, Russian Federation, Revenue ($m), Historic, 2003-2010 50
Figure 27: Other Virology, Russian Federation, Revenue ($m), Forecast, 2010-2017 51
Figure 28: Infectious Immunology, Russian Federation, Company share (%), 2010 53
Figure 29: Infectious Immunology, India, Overall Revenue ($m), USD Actual, 2003-2017 55
Figure 30: Infectious Immunology, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 57
Figure 31: Infectious Immunology, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 59
Figure 32: Hepatitis Viruses, India, Revenue ($m), Historic, 2003-2010 61
Figure 33: Hepatitis Viruses, India, Revenue ($m), Forecast, 2010-2017 62
Figure 34: Retroviruses, India, Revenue ($m), Historic, 2003-2010 63
Figure 35: Retroviruses, India, Revenue ($m), Forecast, 2010-2017 64
Figure 36: Bacteriology, India, Revenue ($m), Historic, 2003-2010 65
Figure 37: Bacteriology, India, Revenue ($m), Forecast, 2010-2017 66
Figure 38: Other Virology, India, Revenue ($m), Historic, 2003-2010 67
Figure 39: Other Virology, India, Revenue ($m), Forecast, 2010-2017 68
Figure 40: Infectious Immunology, India, Company share (%), 2010 70
Figure 41: Infectious Immunology, China, Overall Revenue ($m), USD Actual, 2003-2017 72
Figure 42: Infectious Immunology, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 74
Figure 43: Infectious Immunology, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 76
Figure 44: Retroviruses, China, Revenue ($m), Historic, 2003-2010 78
Figure 45: Retroviruses, China, Revenue ($m), Forecast, 2010-2017 79
Figure 46: Hepatitis Viruses, China, Revenue ($m), Historic, 2003-2010 80
Figure 47: Hepatitis Viruses, China, Revenue ($m), Forecast, 2010-2017 81
Figure 48: Other Virology, China, Revenue ($m), Historic, 2003-2010 82
Figure 49: Other Virology, China, Revenue ($m), Forecast, 2010-2017 83
Figure 50: Bacteriology, China, Revenue ($m), Historic, 2003-2010 84
Figure 51: Bacteriology, China, Revenue ($m), Forecast, 2010-2017 85
Figure 52: Infectious Immunology, China, Company share (%), 2010 87
Figure 53: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 89
Figure 54: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 91
Figure 55: Infectious Immunology, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 93
Figure 56: Retroviruses, South Africa, Revenue ($m), Historic, 2003-2010 95
Figure 57: Retroviruses, South Africa, Revenue ($m), Forecast, 2010-2017 96
Figure 58: Hepatitis Viruses, South Africa, Revenue ($m), Historic, 2003-2010 97
Figure 59: Hepatitis Viruses, South Africa, Revenue ($m), Forecast, 2010-2017 98
Figure 60: Other Virology, South Africa, Revenue ($m), Historic, 2003-2010 99
Figure 61: Other Virology, South Africa, Revenue ($m), Forecast, 2010-2017 100
Figure 62: Bacteriology, South Africa, Revenue ($m), Historic, 2003-2010 101
Figure 63: Bacteriology, South Africa, Revenue ($m), Forecast, 2010-2017 102
Figure 64: Infectious Immunology, South Africa, Company share (%), 2010 104
Figure 65: Abbott Laboratories, Company Share (%), BRICS Infectious Immunology Market, 2010 107
Figure 66: F. Hoffmann-La Roche Ltd., Company Share (%), BRICS Infectious Immunology Market, 2010 109
Figure 67: Siemens Healthcare, Company Share (%), BRICS Infectious Immunology Market, 2010 111
Figure 68: bioMerieux S.A., Company Share (%), BRICS Infectious Immunology Market, 2010 113
Figure 69: DiaSorin S.p.A, Company Share (%), BRICS Infectious Immunology Market, 2010 115
Figure 70: Qiagen N.V., Company Share (%), BRICS Infectious Immunology Market, 2010 117
Figure 71: Gen-Probe Incorporated, Company Share (%), BRICS Infectious Immunology Market, 2010 120
Figure 72: Beckman Coulter, Inc., Company Share (%), BRICS Infectious Immunology Market, 2010 122
Figure 73: Bio-Rad Laboratories, Inc., Company Share (%), BRICS Infectious Immunology Market, 2010 124
Figure 74: Becton, Dickinson and Company, Company Share (%), BRICS Infectious Immunology Market, 2010 126

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

金磚5國各國的感染免疫學市場展望(～2017年)

Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017